US/UK/Canada

Share

Contacts

  • BIOINVENT
    Sölvegatan 41 223 70 LUND
    +46 46 286 85 50
    +46 46 211 08 06
    http://www.bioinvent.com

    • Quotes

    FDA approval of the Phase I/IIa study of BI-1808 is another important milestone for BioInvent as we continue to broaden our exciting pipeline of anti-cancer antibodies. TNFR2 is increasingly attracting interest as revealed by the recent deals in the field. The development of BI-1808 is supported by an impressive set of preclinical data and is one of three BioInvent lead candidates in clinical development.
    Martin Welschof, CEO BioInvent International
    The data on BI-1607 are very exciting and provide proof-of-concept of its ability to enhance anti-cancer immunity, illustrated by its ability to boost activity and overcome resistance to CTLA-4-based therapy. We are looking forward to advancing BI-1607 into clinical development and expect to submit a clinical trial application during H2 2021. It will be BioInvent’s fourth drug candidate in clinical development, further demonstrating the strength and productivity of our technology platform.
    Martin Welschof, CEO
    Pick a time period -
    Tags ( Active)

    BioInvent Announces Second Clinical Trial Collaboration and Supply Agreement to Evaluate BI-1808 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Solid Tumors

    · Anti-TNFR2 antibody targets Treg mediated immunosuppression · Agreement supports the strong rationale for combining anti-TNFR2 and pembrolizumab in the ongoing Phase 1/2a trial · BI-1808 is one of three BioInvent drug candidates in clinical development Lund, Sweden – August 6, 2021 – BioInvent International AB (“BioInvent”) (Nasdaq Stockholm: BINV) today announced that it has entered into a second clinical trial collaboration and supply agreement with MSD, a tradename of Merck & Co., Inc., Kenilworth, NJ., USA, to evaluate the combination of BioInvent’s BI-1808, one of its

    Annual Report 2017

    Lund, Sweden – 3 April 2018 – BioInvent International AB (OMXS: BINV) today announces that the Annual Report for 2017 now is available at the company’s website, www.bioinvent.com.     Notes to editors: About BioInventBioInvent International AB (OMXS: BINV) is focused on the discovery and development of novel and first-in-class immuno-regulatory antibodies to treat cancer. The Company’s clinical programmes are BI-1206, currently in a Phase I/II for non-Hodgkin’s lymphoma and chronic lymphatic leukaemia and TB- 403, in cooperation with Oncurious, currently in Phase I/II for

    European Patent Office intends to grant BioInvent patent relevant to its F.I.R.S.T.™ platform

    Lund, Sweden – 17 January 2018 – BioInvent International AB (OMXS: BINV) announces today that the European Patent Office, EPO, has communicated its intention to grant the company a patent relevant to its unique, function-based F.I.R.S.T.™ platform. More precisely, the patent builds on earlier F.I.R.S.T.™ patents, extending protection to combined use of differential biopanning and high throughput sequencing, such as NGS in identification of antibodies to low expressed cell surface antigens. The European patent should be granted by the EPO once all remaining administrative actions have been

    Annual Report 2016

    Lund, Sweden – 12 April 2017 – BioInvent International AB (OMXS: BINV) today announces that the Annual Report for 2016 now is available at the company’s website, www.bioinvent.com.Notes to editors: About BioInvent BioInvent International AB (OMXS: BINV) is focused on the discovery and development of novel and first-in-class immuno-regulatory antibodies to treat cancer. The Company’s clinical programmes are BI-1206, currently in a Phase I/II for non-Hodgkin’s lymphoma and chronic lymphatic leukaemia and TB-403, in cooperation with Oncurious, currently in Phase I/II for medulloblastoma.

    Management's shareholding after completion of the rights issue

    Lund, Sweden – 15 June, 2015 – BioInvent International AB (publ) (OMXS:BINV) has previously announced that members of BioInvent’s management and key personnel have, in addition to existing holdings, purchased subscription rights and subscribed for new shares corresponding to a total of 2.8 per cent of the shares offered in the rights issue completed in May 2015. Following the completion of the rights issue Management’s changes in shareholdings are presented. +----------------------------+----------+--------+----------------------+|Management's shareholding |Before the| Changes|After

    BioInvent receives clinical milestone in partner program

    Lund, Sweden – 8 July 2013 - BioInvent International (OMXS:BINV) today announces that it will receive a milestone payment in connection with a partner’s start of a phase I clinical study using a n-CoDeR® antibody. BioInvent’s pipeline of external drug programmes consists of another seven antibodies in pre-clinical development of which additional candidates are expected to enter clinical trials in 2013. Cristina Glad, CEO of BioInvent, commented: “The advancement by one of our partners of an n-CoDeR® antibody into the clinic is an important step forward for BioInvent. Progress in our

    BioInvent focuses its business

    Lund, Sweden – 2 October 2012 – BioInvent International AB (OMXS:BINV) announces today that the company has decided to focus its operations with the aim of achieving self-financing of the business before external costs for future new clinical studies. Its development of proprietary antibody drugs will concentrate primarily on developing new cancer drugs, resulting in a clear indication focus. The company currently has five agreements with major companies based on products from the antibody library, n-CoDeR®. The company will increase the efforts to create new n‑CoDeR agreements for clinical

    BioInvent holds Capital Markets Day in Stockholm

    Detailed review of BioInvent’s programmes, including its lead products, BI-204 (cardiovascular disease) and TB-402 (anti-Factor VIII)Lund, Sweden–8 November 2011 – BioInvent International AB (OMXS: BINV) will hold its first Capital Markets Day for investors, analysts and media today. The event will be hosted by Svein Mathisen, CEO, and Sten Westerberg, VP IR of BioInvent. They will be supported by members of the senior team, including Steven Glazer MD, Senior Vice President, Development, Martin Wiles, Senior Vice President, Business Development, Björn Frendéus, Vice President,

    Annual General Meeting in BioInvent International AB

    The shareholders of BioInvent International AB (publ), reg no 556537-7263, are hereby invited to attend the Annual General Meeting (the “AGM”) to be held at 4 p.m., Thursday March 24, 2011 at Edison Park, Emdalavägen 16 in Lund, Sweden. N.B. New place of meeting! A.                         NOTICE OF ATTENDANCE Shareholders who wish to attend the AGM must: (i)                be recorded in the printout of the share register maintained by Euroclear Sweden AB (“Euroclear”), as of Friday March 18, 2011; and (ii)               notify the company of their intention to attend the

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe